Table I.

Selected recent publications in characterization and understanding of process‐related impurities

Subject matter	Publications	Author's affiliation
Identification of critical HCPs	Levy et al. (2013), Aboulaich et al. (2014), Eon‐Duval et al. (2012), Wang et al. (2009), Valente et al. (2013), Beatson et al. (2011), Bomans et al. (2013)	Genentech, MedImmune, Uni. Delaware, Merck Serono, Pfizer, Kings, Roche, Merck (US)
HCP Process interactions	Shukla et al. (2008), Hunter et al. (2009), Aboulaich et al. (2014), Hogwood et al. (2013), Nogal et al. (2012), Tait et al. (2012), Tarrant et al. (2012), Trexler‐Schmidt et al. (2010), Joucla et al. (2013), Levy et al. (2014), Gagnon et al. (2014)	Bristol‐Myers Squibb, Pfizer, MedImmune, UCL, Uni. Kent, Genentech, Bordeaux Uni., BTI Singapore
HCP‐associated product damage	Kao et al. (2010), Dorai et al. (2011), Sandberg et al. (2006), Trexler‐Schmidt et al. (2010), Gao et al. (2011), Robert et al. (2009)	Genentech, Centocor, Biogen Idec, Biovitrum, Merck Serono